Kubina Robert, Dziedzic Arkadiusz
Department of Pathology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland.
Department of Conservative Dentistry with Endodontics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Diagnostics (Basel). 2020 Jun 26;10(6):434. doi: 10.3390/diagnostics10060434.
Validated and accurate laboratory testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a crucial part of the timely management of Coronavirus Disease 2019 (COVID-19) disease, supporting the clinical decision-making process for infection control at the healthcare level and detecting asymptomatic cases. This would facilitate an appropriate treatment, a prompt isolation and consequently deceleration of the pandemic. Various laboratory tests can identify the genetic material of SARS-CoV-2 that causes COVID-19 in specimens, or specific anti-viral antibodies in blood/serum. Due to the current pandemic situation, a development of point-of-care diagnostics (POCD) allows us to substantially accelerate taking clinical decisions and implement strategic planning at the national level of preventative measures. This review summarizes and compares the available POCD and those currently under development, including quantitative reverse transcription PCR (RT-qPCR), serology immunoassays (SIAs) and protein microarray method (PMM) designed for standard and rapid COVID-19 diagnosis.
针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的经过验证且准确的实验室检测,是2019冠状病毒病(COVID-19)及时管理的关键部分,有助于医疗层面感染控制的临床决策过程,并能检测出无症状病例。这将有助于进行适当治疗、迅速隔离,从而减缓疫情传播。各种实验室检测可以识别标本中导致COVID-19的SARS-CoV-2的遗传物质,或血液/血清中的特定抗病毒抗体。鉴于当前的疫情形势,即时检测诊断(POCD)的发展使我们能够大幅加快临床决策速度,并在国家层面实施预防措施的战略规划。本综述总结并比较了现有的即时检测诊断方法以及目前正在开发的方法,包括用于标准和快速COVID-19诊断的定量逆转录聚合酶链反应(RT-qPCR)、血清学免疫测定(SIA)和蛋白质微阵列方法(PMM)。